BUSINESS ADVISORY COMMITTEE
Combining the expertise of proven investment professionals and world-renowned clinicians
BioStar Capital has established a Business Advisory Committee (BAC) for each of its Funds. The role of the BAC is to (1) review the valuation of the Fund’s portfolio on a periodic basis; (2) provide guidance to the Fund’s Managing Directors on matters involving investment policies and strategies, (3) address waiver requests that involve percentage ownership or other investment restrictions and to evaluate cross-over investment proposals on a case-by-case basis; (4) review any transaction between (i) the Fund or a portfolio company and (ii) another BioStar Fund, the General Partner, one of its Managing Directors, the Medical Venture Partners, or their affiliates, if there is the potential for conflict of interest, as well as any other conflict of interest matters that may be presented to it.
The following individuals serve as voting members of the BAC for BioStar III.
Jim Bennethum brings a diverse background of proven global operational and business development experience. Jim has led several successful global businesses; leveraging high impact multinational leadership teams, with full P&L responsibility. In the past several years Jim has been responsible for $3 Billion in annual revenue which included the operations of core businesses while building a profitable backlog through world class execution, innovative product offerings and winning customer relationships. Jim is experienced in complex business operations, joint ventures, emerging market development and restructuring activities in all major regions of the world. Jim has demonstrated success in both the private and public sectors with proven capabilities deploying entrepreneurialism side by side with complex process disciplines. With over 28 years of automotive systems development and manufacturing experience, he has recently made an emerging impact in the Health Care / Pharma industry. In addition to serving as a Board Member for the Karmanos Cancer Institute in South East Michigan, Jim is an Executive Vice President at Becker Ventures, LLC and a Director at Velicept Therapeutics. Jim’s past experience includes key positions in leading automotive companies (including Johnson Controls, Becker Group and Textron), most recently completing over 20 years in senior leadership roles at Johnson Controls, Inc.. Johnson Controls is a global diversified technology and industrial leader serving customers in more than 150 countries, with over 162,000 employees. Jim earned a BS in Technology Management from Eastern Michigan University, and resides in Michigan with his wife Jennifer and their four children.
Dennis Branoff has extensive experience owning and operating business start-ups and mature companies and offers business insight to support identifying opportunities, growth and operational development. As of January 1, 2010, he acquired Apartment Insurance Consultants, which is one of the nation’s oldest habitational management insurance businesses in the country. In 2007, Mr. Branoff sold his student housing Atlantis Campus Communities business to the Pierce Company of San Diego, CA, which according to Real Capital Analytics, was the largest transaction for student housing in the country. Prior to selling the company, Mr. Branoff was a large international business operator for thirty years, owning and managing the Weight Watchers business in Italy, Greece, Cyprus, and in Michigan and Indiana, which he sold in 2006 to the parent company (Artal, SA) of Weight Watchers International, Inc. Mr. Branoff has owned and operated a software development company which he also sold in 2006, and has business ownership and operational experience in other industries as well. Mr. Branoff attended the University of Michigan at Ann Arbor, Michigan and the International Honors University of Santander, at Santander, Spain.
The following individuals serve as voting members of the BAC for BioStar II.
David J. Brophy, PhD
David Brophy, PhD is the Director of the University of Michigan Business School Center for Venture Capital and Private Equity. He is also a member of the Finance and Entrepreneurial Studies Faculty at the University of Michigan School of Business Administration (UMBS) where he teaches courses in corporate valuation, venture capital and both domestic and international private equity and finance. Dr. Brophy is active internationally in the field of venture capital and private equity finance, entrepreneurship and initiated the process of information surveying for the National Venture Capital Association, a process that is now the major source of information on the venture capital market. Dr. Brophy has advised several institutional and corporate investors in their private equity finance activities. He has been a director of several public companies and is a director and consultant to banks, money market funds, and financial services firms.
The following individuals serve as voting members of the BAC for BioStar I.
Paul Buckman currently serves as President and CEO of SentreHeart, Inc. Mr. Buckman has 35 years of management experience in sales, marketing and general management, with senior management roles at several medical device companies including Scimed, DVI and American Hospital Supply. His experience also includes serving as President and CEO of Pathway Medical Devices, CEO and co-founder of ev3, President, Cardiology at Boston Scientific, and President, Cardiology and St. Jude.
Chris Miller served as a Director and CFO of Star Scientific, a public traded NASDAQ company. Prior to and overlapping with that time, Mr. Miller was the founder and CEO of the Special Opportunities Group, and beforehand, the Founder and CEO of American Health Care Limited and International Medical Care Limited. He also served as CFO of HCA International and CFO of BioStar Private Equity PEF and BioStar Private Equity PEF, FP from 2008 – 2010. Mr. Miller graduated from West Point and holds an MBA from the Harvard Business School.